Saliva Collection Devices Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Whole Saliva Collection Devices and Glandular Saliva Collection Devices), By Application (Pharma and Biotech Companies, Forensics, Dentistry, Diagnostic and Pathology Laboratories, and Research Institutes), and Region Forecast 2019-2030

Saliva Collection Devices Market size was valued at US$ 363.3 million in 2023 and is poised to grow at a CAGR of 14.9% from 2024-2030. Increased approvals for saliva collection devices are expected to drive growth in the market due to the growing need for rapid diagnosis of life-threatening diseases. Furthermore, technological advancements in infant saliva collection are expected to drive the growth of the market. For example, Oasis Diagnostics created the Pedia SAL collection kit for infants. It enables saliva collection with the simplest design, with the goal of not only collecting saliva samples but also relaxing infants during the procedure. As the number of ailments increases, so will the number of clinical trials conducted by the government, creating new opportunities for the growth of the market.

The opportunity for point of care test kits is increasing due to mandating of drug abuse testing for employees, drivers, and person working at hazardous jobs. Development and launch of point-of-care test kits may enhance the revenue of market over the forecast timeframe. For instance, in January 2019, Alere received FDA 510(k) clearance of two new drug screening tests offer practitioner rapid, in-office results for the most abused opioid-derived drugs using urine sample. In the market, the biotech companies segment expected to contribute the highest revenue share of 67.8% in 2021. The biotech companies' rapid advancements and innovative technologies may boost the market.

Key Developments

• In Jan 2020, Salimetrics Introduced a New Salivary Human Total Immunoglobulin G (IgG) ELISA Kit to Aid Multidisciplinary Serological Researchers. The launch of this Salimetrics Salivary IgG Assay Kit is the result of extensive collaboration with public health researchers.
• In Sept 2020, QIAGEN acquired NeuMoDx Molecular, Inc. The NeuMoDx systems full integration will enable QIAGEN to meet laboratory needs for molecular diagnostics in practically any situation.